|
EAPP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.68569996534296E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.70389999998299E-07 |
| Normal-vs-Stage2 |
2.205100E-04 |
| Normal-vs-Stage3 |
7.62020000433239E-08 |
| Normal-vs-Stage4 |
8.57589554925653E-11 |
| Stage1-vs-Stage2 |
9.957400E-01 |
| Stage1-vs-Stage3 |
2.259200E-01 |
| Stage1-vs-Stage4 |
4.156900E-03 |
| Stage2-vs-Stage3 |
4.494800E-01 |
| Stage2-vs-Stage4 |
7.232100E-02 |
| Stage3-vs-Stage4 |
1.465410E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.19940002374364E-09 |
| Normal-vs-AfricanAmerican |
1.474010E-02 |
| Normal-vs-Asian |
8.978500E-04 |
| Caucasian-vs-AfricanAmerican |
1.750400E-01 |
| Caucasian-vs-Asian |
1.734790E-01 |
| AfricanAmerican-vs-Asian |
7.941800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.52740000039609E-07 |
| Normal-vs-Female |
1.383500003449E-08 |
| Male-vs-Female |
8.765800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.32859999954793E-07 |
| Normal-vs-Age(41-60Yrs) |
1.5778999999938E-06 |
| Normal-vs-Age(61-80Yrs) |
1.97630023457407E-10 |
| Normal-vs-Age(81-100Yrs) |
6.589500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.708400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.474100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.383000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.702400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.380800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.660400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.093800E-02 |
| Classical-VS-Follicular |
4.732300E-02 |
| Classical-VS-Other |
6.114600E-01 |
| Classical-VS-Normal |
1.65420000031169E-07 |
| Tall-VS-Follicular |
8.096800E-01 |
| Tall-VS-Other |
6.093600E-01 |
| Tall-VS-Normal |
4.14079999955241E-07 |
| Follicular-VS-Other |
7.893200E-01 |
| Follicular-VS-Normal |
1.91569999974384E-07 |
| Other-VS-Normal |
1.831860E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.61910001756405E-09 |
| Normal-vs-N1 |
2.71669999829527E-08 |
| N0-vs-N1 |
3.173800E-01 |
|
|
